Collegium Pharmaceutical has agreed to acquire AZSTARYS from privately held Corium Therapeutics Holdings for $650 million in cash at closing23
The deal includes $135 million in potential milestone payments, bringing the total value to up to $785 million25
AZSTARYS is an ADHD medication being acquired as part of Collegium's strategy to expand its product portfolio2
The acquisition is expected to drive additional topline revenue growth for Collegium in 20266
Sources:
2. https://www.fiercepharma.com/pharma/collegium-ponies-650m-gain-adhd-drug-azstarys-corium
3. https://www.gurufocus.com/news/8726647/collegium-pharmaceutical-coll-to-acquire-azstarys-for-650-million
5. https://www.tradingview.com/news/reuters.com,2026:newsml_L4N4071DC:0-collegium-pharmaceutical-to-acquire-corium-s-adhd-drug-for-up-to-785-million/
6. https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/tm262493d1_ex99-1.htm